Evolus, Inc.
About Evolus, Inc.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $297.2M
- Net income
- -$51.6M
- Total assets
- $225.9M
- Market cap
- $439.3M
- Gross margin
- 66.3%
- Operating margin
- -11.0%
- Net margin
- -17.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $297.2M
- Cost of revenue
- $100.1M
- Gross profit
- $197.1M
- Operating expenses
- $229.8M
- Operating income
- -$32.7M
- Income tax
- $677.0K
- Net income
- -$51.6M
- EPS (basic)
- $-0.80
- EPS (diluted)
- $-0.80
Balance sheet
- Total assets
- $225.9M
- Current assets
- $142.9M
- Total liabilities
- $249.0M
- Current liabilities
- $75.3M
- Shareholders’ equity
- -$23.1M
Cash flow
- Operating cash flow
- -$42.3M
- Investing cash flow
- -$8.5M
- Financing cash flow
- $17.3M
- Net cash flow
- -$33.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $439.3M
- EPS (diluted)
- $-0.8
- Shares outstanding
- 65.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 8, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $51.6M in FY2025.
- Revenue grew 198% from FY2021 to FY2025.
- Gross margin of 66.3%, net margin -17.4%.
- Trading 44% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Evolus, Inc..
Write a review
News about Evolus, Inc.
News & sentiment via Polygon.io
